#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Within this study , we used real-time CGM ( rtCGM ) in combination with a serial analysis of blood and exhaled breath in a highly standardized setting in pediatric T1DM patients and healthy controls over a time course of nine hours .
2-1	14-20	Within	_	_	_	_
2-2	21-25	this	abstract[2]	new[2]	coref	17-25[139_2]
2-3	26-31	study	abstract[2]	new[2]	_	_
2-4	32-33	,	_	_	_	_
2-5	34-36	we	person	acc	ana	3-1
2-6	37-41	used	_	_	_	_
2-7	42-51	real-time	abstract[4]	new[4]	appos	2-10[0_4]
2-8	52-55	CGM	abstract[4]	new[4]	_	_
2-9	56-57	(	_	_	_	_
2-10	58-63	rtCGM	abstract	giv	_	_
2-11	64-65	)	_	_	_	_
2-12	66-68	in	_	_	_	_
2-13	69-80	combination	_	_	_	_
2-14	81-85	with	_	_	_	_
2-15	86-87	a	abstract[6]	new[6]	coref	5-2[41_6]
2-16	88-94	serial	abstract[6]	new[6]	_	_
2-17	95-103	analysis	abstract[6]	new[6]	_	_
2-18	104-106	of	abstract[6]	new[6]	_	_
2-19	107-112	blood	abstract[6]|substance	new[6]|new	coref	3-16
2-20	113-116	and	abstract[6]	new[6]	_	_
2-21	117-124	exhaled	abstract[6]|abstract[8]	new[6]|new[8]	coref	3-8[0_8]
2-22	125-131	breath	abstract[6]|abstract[8]	new[6]|new[8]	_	_
2-23	132-134	in	_	_	_	_
2-24	135-136	a	abstract[9]	new[9]	_	_
2-25	137-143	highly	abstract[9]	new[9]	_	_
2-26	144-156	standardized	abstract[9]	new[9]	_	_
2-27	157-164	setting	abstract[9]	new[9]	_	_
2-28	165-167	in	abstract[9]	new[9]	_	_
2-29	168-177	pediatric	abstract[9]|person[11]|person[12]	new[9]|new[11]|new[12]	coref|coref	11-16[86_11]|21-25[175_12]
2-30	178-182	T1DM	abstract[9]|abstract|person[11]|person[12]	new[9]|new|new[11]|new[12]	coref	8-5
2-31	183-191	patients	abstract[9]|person[11]|person[12]	new[9]|new[11]|new[12]	_	_
2-32	192-195	and	abstract[9]|person[12]	new[9]|new[12]	_	_
2-33	196-203	healthy	abstract[9]|person[12]|event[13]	new[9]|new[12]|new[13]	coref	11-20[0_13]
2-34	204-212	controls	abstract[9]|person[12]|event[13]	new[9]|new[12]|new[13]	_	_
2-35	213-217	over	abstract[9]	new[9]	_	_
2-36	218-219	a	abstract[9]|time[14]	new[9]|new[14]	coref	12-15[97_14]
2-37	220-224	time	abstract[9]|time[14]	new[9]|new[14]	_	_
2-38	225-231	course	abstract[9]|time[14]	new[9]|new[14]	_	_
2-39	232-234	of	abstract[9]|time[14]	new[9]|new[14]	_	_
2-40	235-239	nine	abstract[9]|time[14]|time[15]	new[9]|new[14]|new[15]	coref	12-15[98_15]
2-41	240-245	hours	abstract[9]|time[14]|time[15]	new[9]|new[14]|new[15]	_	_
2-42	246-247	.	_	_	_	_

#Text=We accumulated more than 4000 measurements of breath VOCs and interstitial glucose and almost 1000 blood samples from 44 participants .
3-1	248-250	We	person	giv	ana	5-11
3-2	251-262	accumulated	_	_	_	_
3-3	263-267	more	abstract[17]	new[17]	_	_
3-4	268-272	than	abstract[17]	new[17]	_	_
3-5	273-277	4000	abstract[17]	new[17]	_	_
3-6	278-290	measurements	abstract[17]	new[17]	_	_
3-7	291-293	of	abstract[17]	new[17]	_	_
3-8	294-300	breath	abstract[17]|abstract|abstract[19]	new[17]|giv|new[19]	coref|coref	4-25|7-19[63_19]
3-9	301-305	VOCs	abstract[17]|abstract[19]	new[17]|new[19]	_	_
3-10	306-309	and	abstract[17]	new[17]	_	_
3-11	310-322	interstitial	abstract[17]|substance[20]	new[17]|new[20]	coref	6-7[0_20]
3-12	323-330	glucose	abstract[17]|substance[20]	new[17]|new[20]	_	_
3-13	331-334	and	_	_	_	_
3-14	335-341	almost	object[22]	new[22]	_	_
3-15	342-346	1000	object[22]	new[22]	_	_
3-16	347-352	blood	substance|object[22]	giv|new[22]	coref	4-38
3-17	353-360	samples	object[22]	new[22]	_	_
3-18	361-365	from	object[22]	new[22]	_	_
3-19	366-368	44	object[22]|person[23]	new[22]|new[23]	_	_
3-20	369-381	participants	object[22]|person[23]	new[22]|new[23]	_	_
3-21	382-383	.	_	_	_	_

#Text=Standardization with respect to physical activity , the interval between meals , the type and amount of nutrients , and the restriction to alveolar breath sampling allows the generation of highly comparable diurnal profiles of breath and blood born parameters relative to the metabolic state .
4-1	384-399	Standardization	abstract[24]	new[24]	_	_
4-2	400-404	with	abstract[24]	new[24]	_	_
4-3	405-412	respect	abstract[24]	new[24]	_	_
4-4	413-415	to	abstract[24]	new[24]	_	_
4-5	416-424	physical	abstract[24]|abstract[25]	new[24]|new[25]	_	_
4-6	425-433	activity	abstract[24]|abstract[25]	new[24]|new[25]	_	_
4-7	434-435	,	abstract[24]	new[24]	_	_
4-8	436-439	the	abstract[24]|abstract[26]	new[24]|new[26]	coref	12-18[99_26]
4-9	440-448	interval	abstract[24]|abstract[26]	new[24]|new[26]	_	_
4-10	449-456	between	abstract[24]|abstract[26]	new[24]|new[26]	_	_
4-11	457-462	meals	abstract[24]|abstract[26]|event	new[24]|new[26]|new	coref	24-30
4-12	463-464	,	_	_	_	_
4-13	465-468	the	abstract[28]	new[28]	_	_
4-14	469-473	type	abstract[28]	new[28]	_	_
4-15	474-477	and	_	_	_	_
4-16	478-484	amount	abstract[29]	new[29]	coref	10-17[79_29]
4-17	485-487	of	abstract[29]	new[29]	_	_
4-18	488-497	nutrients	abstract[29]|substance	new[29]|new	_	_
4-19	498-499	,	_	_	_	_
4-20	500-503	and	_	_	_	_
4-21	504-507	the	abstract[31]	new[31]	_	_
4-22	508-519	restriction	abstract[31]	new[31]	_	_
4-23	520-522	to	abstract[31]	new[31]	_	_
4-24	523-531	alveolar	abstract[31]|abstract[33]	new[31]|new[33]	coref	7-11[62_33]
4-25	532-538	breath	abstract[31]|abstract|abstract[33]	new[31]|giv|new[33]	coref	4-36
4-26	539-547	sampling	abstract[31]|abstract[33]	new[31]|new[33]	_	_
4-27	548-554	allows	_	_	_	_
4-28	555-558	the	person[34]	new[34]	_	_
4-29	559-569	generation	person[34]	new[34]	_	_
4-30	570-572	of	person[34]	new[34]	_	_
4-31	573-579	highly	person[34]|abstract[35]	new[34]|new[35]	_	_
4-32	580-590	comparable	person[34]|abstract[35]	new[34]|new[35]	_	_
4-33	591-598	diurnal	person[34]|abstract[35]	new[34]|new[35]	_	_
4-34	599-607	profiles	person[34]|abstract[35]	new[34]|new[35]	_	_
4-35	608-610	of	person[34]|abstract[35]	new[34]|new[35]	_	_
4-36	611-617	breath	person[34]|abstract[35]|abstract|abstract[38]	new[34]|new[35]|giv|new[38]	coref	5-3
4-37	618-621	and	person[34]|abstract[35]|abstract[38]	new[34]|new[35]|new[38]	_	_
4-38	622-627	blood	person[34]|abstract[35]|substance|abstract[38]	new[34]|new[35]|giv|new[38]	coref	7-12
4-39	628-632	born	person[34]|abstract[35]|abstract[38]	new[34]|new[35]|new[38]	_	_
4-40	633-643	parameters	person[34]|abstract[35]|abstract[38]	new[34]|new[35]|new[38]	_	_
4-41	644-652	relative	person[34]|abstract[35]|abstract[38]	new[34]|new[35]|new[38]	_	_
4-42	653-655	to	_	_	_	_
4-43	656-659	the	abstract[39]	new[39]	_	_
4-44	660-669	metabolic	abstract[39]	new[39]	_	_
4-45	670-675	state	abstract[39]	new[39]	_	_
4-46	676-677	.	_	_	_	_

#Text=For real-time breath analysis , a PTR-ToF-MS was used and we focused on the exhalation of ethanol , acetone , isopropanol , dimethyl sulfide , isoprene , pentanal , and limonene .
5-1	678-681	For	_	_	_	_
5-2	682-691	real-time	abstract[41]	giv[41]	_	_
5-3	692-698	breath	abstract|abstract[41]	giv|giv[41]	coref	8-15
5-4	699-707	analysis	abstract[41]	giv[41]	_	_
5-5	708-709	,	_	_	_	_
5-6	710-711	a	abstract[42]	new[42]	_	_
5-7	712-722	PTR-ToF-MS	abstract[42]	new[42]	_	_
5-8	723-726	was	_	_	_	_
5-9	727-731	used	_	_	_	_
5-10	732-735	and	_	_	_	_
5-11	736-738	we	person	giv	ana	7-3
5-12	739-746	focused	_	_	_	_
5-13	747-749	on	_	_	_	_
5-14	750-753	the	event[44]	new[44]	_	_
5-15	754-764	exhalation	event[44]	new[44]	_	_
5-16	765-767	of	event[44]	new[44]	_	_
5-17	768-775	ethanol	event[44]|substance	new[44]|new	_	_
5-18	776-777	,	event[44]	new[44]	_	_
5-19	778-785	acetone	event[44]|substance	new[44]|new	coref	8-7
5-20	786-787	,	event[44]	new[44]	_	_
5-21	788-799	isopropanol	event[44]|substance	new[44]|new	coref	18-17
5-22	800-801	,	event[44]	new[44]	_	_
5-23	802-810	dimethyl	event[44]|abstract|substance[49]	new[44]|new|new[49]	_	_
5-24	811-818	sulfide	event[44]|substance[49]	new[44]|new[49]	_	_
5-25	819-820	,	event[44]	new[44]	_	_
5-26	821-829	isoprene	event[44]|substance	new[44]|new	_	_
5-27	830-831	,	event[44]	new[44]	_	_
5-28	832-840	pentanal	event[44]|substance	new[44]|new	_	_
5-29	841-842	,	event[44]	new[44]	_	_
5-30	843-846	and	event[44]	new[44]	_	_
5-31	847-855	limonene	event[44]|abstract	new[44]|new	_	_
5-32	856-857	.	_	_	_	_

#Text=These compounds have been linked to glucose metabolism and/or to T1DM-related comorbidities including oxidative stress .
6-1	858-863	These	substance[53]	new[53]	_	_
6-2	864-873	compounds	substance[53]	new[53]	_	_
6-3	874-878	have	_	_	_	_
6-4	879-883	been	_	_	_	_
6-5	884-890	linked	_	_	_	_
6-6	891-893	to	_	_	_	_
6-7	894-901	glucose	substance|abstract[55]	giv|new[55]	coref	12-7
6-8	902-912	metabolism	abstract[55]	new[55]	_	_
6-9	913-919	and/or	_	_	_	_
6-10	920-922	to	_	_	_	_
6-11	923-935	T1DM-related	abstract[56]	new[56]	_	_
6-12	936-949	comorbidities	abstract[56]	new[56]	_	_
6-13	950-959	including	abstract[56]	new[56]	_	_
6-14	960-969	oxidative	abstract[56]|abstract[57]	new[56]|new[57]	_	_
6-15	970-976	stress	abstract[56]|abstract[57]	new[56]|new[57]	_	_
6-16	977-978	.	_	_	_	_

#Text=Thus , we investigated the fade of classical markers via repetitive blood sampling and looked in parallel for the VOCs mentioned above .
7-1	979-983	Thus	_	_	_	_
7-2	984-985	,	_	_	_	_
7-3	986-988	we	person	giv	ana	11-5
7-4	989-1001	investigated	_	_	_	_
7-5	1002-1005	the	abstract[59]	new[59]	_	_
7-6	1006-1010	fade	abstract[59]	new[59]	_	_
7-7	1011-1013	of	abstract[59]	new[59]	_	_
7-8	1014-1023	classical	abstract[59]|abstract[60]	new[59]|new[60]	_	_
7-9	1024-1031	markers	abstract[59]|abstract[60]	new[59]|new[60]	_	_
7-10	1032-1035	via	_	_	_	_
7-11	1036-1046	repetitive	abstract[62]	giv[62]	coref	12-25[104_62]
7-12	1047-1052	blood	substance|abstract[62]	giv|giv[62]	coref	11-27
7-13	1053-1061	sampling	abstract[62]	giv[62]	_	_
7-14	1062-1065	and	_	_	_	_
7-15	1066-1072	looked	_	_	_	_
7-16	1073-1075	in	_	_	_	_
7-17	1076-1084	parallel	_	_	_	_
7-18	1085-1088	for	_	_	_	_
7-19	1089-1092	the	abstract[63]	giv[63]	_	_
7-20	1093-1097	VOCs	abstract[63]	giv[63]	_	_
7-21	1098-1107	mentioned	abstract[63]	giv[63]	_	_
7-22	1108-1113	above	abstract[63]	giv[63]	_	_
7-23	1114-1115	.	_	_	_	_

#Text=In the case of T1DM , acetone is certainly the most prominent VOC in breath and has previously been investigated under various conditions .
8-1	1116-1118	In	_	_	_	_
8-2	1119-1122	the	abstract[64]	new[64]	_	_
8-3	1123-1127	case	abstract[64]	new[64]	_	_
8-4	1128-1130	of	abstract[64]	new[64]	_	_
8-5	1131-1135	T1DM	abstract[64]|abstract	new[64]|giv	coref	11-16
8-6	1136-1137	,	_	_	_	_
8-7	1138-1145	acetone	substance	giv	coref	8-9[67_0]
8-8	1146-1148	is	_	_	_	_
8-9	1149-1158	certainly	substance[67]	giv[67]	coref	9-1[0_67]
8-10	1159-1162	the	substance[67]	giv[67]	_	_
8-11	1163-1167	most	substance[67]	giv[67]	_	_
8-12	1168-1177	prominent	substance[67]	giv[67]	_	_
8-13	1178-1181	VOC	substance[67]	giv[67]	_	_
8-14	1182-1184	in	substance[67]	giv[67]	_	_
8-15	1185-1191	breath	substance[67]|abstract	giv[67]|giv	coref	12-25
8-16	1192-1195	and	_	_	_	_
8-17	1196-1199	has	_	_	_	_
8-18	1200-1210	previously	_	_	_	_
8-19	1211-1215	been	_	_	_	_
8-20	1216-1228	investigated	_	_	_	_
8-21	1229-1234	under	_	_	_	_
8-22	1235-1242	various	abstract[69]	new[69]	coref	17-12[134_69]
8-23	1243-1253	conditions	abstract[69]	new[69]	_	_
8-24	1254-1255	.	_	_	_	_

#Text=Acetone originates from enzymatic or non-enzymatic decarboxylation of acetoacetate via Acetyl-CoA which is derived from pyruvate .
9-1	1256-1263	Acetone	substance	giv	coref	11-14
9-2	1264-1274	originates	_	_	_	_
9-3	1275-1279	from	_	_	_	_
9-4	1280-1289	enzymatic	abstract[71]	new[71]	_	_
9-5	1290-1292	or	abstract[71]	new[71]	_	_
9-6	1293-1306	non-enzymatic	abstract[71]	new[71]	_	_
9-7	1307-1322	decarboxylation	abstract[71]	new[71]	_	_
9-8	1323-1325	of	abstract[71]	new[71]	_	_
9-9	1326-1338	acetoacetate	abstract[71]|substance	new[71]|new	_	_
9-10	1339-1342	via	abstract[71]	new[71]	_	_
9-11	1343-1353	Acetyl-CoA	abstract[71]|substance[73]	new[71]|new[73]	_	_
9-12	1354-1359	which	abstract[71]|substance[73]	new[71]|new[73]	_	_
9-13	1360-1362	is	abstract[71]|substance[73]	new[71]|new[73]	_	_
9-14	1363-1370	derived	abstract[71]|substance[73]	new[71]|new[73]	_	_
9-15	1371-1375	from	abstract[71]|substance[73]	new[71]|new[73]	_	_
9-16	1376-1384	pyruvate	abstract[71]|substance[73]|substance	new[71]|new[73]|new	_	_
9-17	1385-1386	.	_	_	_	_

#Text=Since the latter can originate from both glycolysis and lipolysis , it is impossible to differentiate the amount from either pathway .
10-1	1387-1392	Since	_	_	_	_
10-2	1393-1396	the	abstract[75]	new[75]	ana	10-12[0_75]
10-3	1397-1403	latter	abstract[75]	new[75]	_	_
10-4	1404-1407	can	_	_	_	_
10-5	1408-1417	originate	_	_	_	_
10-6	1418-1422	from	_	_	_	_
10-7	1423-1427	both	substance[76]	new[76]	coref	13-28[0_76]
10-8	1428-1438	glycolysis	substance[76]	new[76]	_	_
10-9	1439-1442	and	_	_	_	_
10-10	1443-1452	lipolysis	substance	new	coref	13-26
10-11	1453-1454	,	_	_	_	_
10-12	1455-1457	it	abstract	giv	_	_
10-13	1458-1460	is	_	_	_	_
10-14	1461-1471	impossible	_	_	_	_
10-15	1472-1474	to	_	_	_	_
10-16	1475-1488	differentiate	_	_	_	_
10-17	1489-1492	the	abstract[79]	giv[79]	_	_
10-18	1493-1499	amount	abstract[79]	giv[79]	_	_
10-19	1500-1504	from	_	_	_	_
10-20	1505-1511	either	abstract[80]	new[80]	coref	20-5[159_80]
10-21	1512-1519	pathway	abstract[80]	new[80]	_	_
10-22	1520-1521	.	_	_	_	_

#Text=Regardless of this , we and others noted the significantly elevated exhalation of acetone in T1DM patients compared to controls , as well as the elevated blood levels in T1DM patients .
11-1	1522-1532	Regardless	_	_	_	_
11-2	1533-1535	of	_	_	_	_
11-3	1536-1540	this	_	_	_	_
11-4	1541-1542	,	_	_	_	_
11-5	1543-1545	we	person	giv	ana	17-25
11-6	1546-1549	and	_	_	_	_
11-7	1550-1556	others	person	new	_	_
11-8	1557-1562	noted	_	_	_	_
11-9	1563-1566	the	event[83]	new[83]	_	_
11-10	1567-1580	significantly	event[83]	new[83]	_	_
11-11	1581-1589	elevated	event[83]	new[83]	_	_
11-12	1590-1600	exhalation	event[83]	new[83]	_	_
11-13	1601-1603	of	event[83]	new[83]	_	_
11-14	1604-1611	acetone	event[83]|substance	new[83]|giv	coref	12-9
11-15	1612-1614	in	event[83]	new[83]	_	_
11-16	1615-1619	T1DM	event[83]|abstract|person[86]	new[83]|giv|giv[86]	coref|coref	11-30|11-30[91_86]
11-17	1620-1628	patients	event[83]|person[86]	new[83]|giv[86]	_	_
11-18	1629-1637	compared	_	_	_	_
11-19	1638-1640	to	_	_	_	_
11-20	1641-1649	controls	event	giv	coref	21-28[176_0]
11-21	1650-1651	,	_	_	_	_
11-22	1652-1654	as	_	_	_	_
11-23	1655-1659	well	_	_	_	_
11-24	1660-1662	as	_	_	_	_
11-25	1663-1666	the	abstract[89]	new[89]	coref	23-11[198_89]
11-26	1667-1675	elevated	abstract[89]	new[89]	_	_
11-27	1676-1681	blood	substance|abstract[89]	giv|new[89]	coref	15-9
11-28	1682-1688	levels	abstract[89]	new[89]	_	_
11-29	1689-1691	in	abstract[89]	new[89]	_	_
11-30	1692-1696	T1DM	abstract[89]|abstract|person[91]	new[89]|giv|giv[91]	coref|coref	12-12|12-12[96_91]
11-31	1697-1705	patients	abstract[89]|person[91]	new[89]|giv[91]	_	_
11-32	1706-1707	.	_	_	_	_

#Text=However , although the concentrations of glucose and acetone correlated in T1DM patients , the time and/or the interval between food intake , and breath sampling appears to be an important confounder .
12-1	1708-1715	However	_	_	_	_
12-2	1716-1717	,	_	_	_	_
12-3	1718-1726	although	_	_	_	_
12-4	1727-1730	the	abstract[92]	new[92]	coref	24-26[219_92]
12-5	1731-1745	concentrations	abstract[92]	new[92]	_	_
12-6	1746-1748	of	abstract[92]	new[92]	_	_
12-7	1749-1756	glucose	abstract[92]|substance	new[92]|giv	coref	15-9[127_0]
12-8	1757-1760	and	abstract[92]	new[92]	_	_
12-9	1761-1768	acetone	abstract[92]|substance	new[92]|giv	coref	13-33
12-10	1769-1779	correlated	_	_	_	_
12-11	1780-1782	in	_	_	_	_
12-12	1783-1787	T1DM	abstract|person[96]	giv|giv[96]	coref|coref	19-4|19-4[148_96]
12-13	1788-1796	patients	person[96]	giv[96]	_	_
12-14	1797-1798	,	_	_	_	_
12-15	1799-1802	the	time[97]|time[98]	giv[97]|giv[98]	coref	23-28[205_97]
12-16	1803-1807	time	time[97]|time[98]	giv[97]|giv[98]	_	_
12-17	1808-1814	and/or	time[98]	giv[98]	_	_
12-18	1815-1818	the	time[98]|abstract[99]	giv[98]|giv[99]	_	_
12-19	1819-1827	interval	time[98]|abstract[99]	giv[98]|giv[99]	_	_
12-20	1828-1835	between	time[98]|abstract[99]	giv[98]|giv[99]	_	_
12-21	1836-1840	food	time[98]|abstract[99]|substance|event[101]|event[102]	giv[98]|giv[99]|new|new[101]|new[102]	coref|coref	14-5[118_101]|14-5[119_102]
12-22	1841-1847	intake	time[98]|abstract[99]|event[101]|event[102]	giv[98]|giv[99]|new[101]|new[102]	_	_
12-23	1848-1849	,	time[98]|abstract[99]|event[102]	giv[98]|giv[99]|new[102]	_	_
12-24	1850-1853	and	time[98]|abstract[99]|event[102]	giv[98]|giv[99]|new[102]	_	_
12-25	1854-1860	breath	time[98]|abstract[99]|event[102]|abstract|abstract[104]	giv[98]|giv[99]|new[102]|giv|giv[104]	coref	28-6
12-26	1861-1869	sampling	time[98]|abstract[99]|event[102]|abstract[104]	giv[98]|giv[99]|new[102]|giv[104]	_	_
12-27	1870-1877	appears	_	_	_	_
12-28	1878-1880	to	_	_	_	_
12-29	1881-1883	be	_	_	_	_
12-30	1884-1886	an	abstract[105]	new[105]	_	_
12-31	1887-1896	important	abstract[105]	new[105]	_	_
12-32	1897-1907	confounder	abstract[105]	new[105]	_	_
12-33	1908-1909	.	_	_	_	_

#Text=In the morning , when ketogenesis is high due to overnight fasting , correlations were low , most probably due to an additive effect of lipolysis and glycolysis on the formation of acetone .
13-1	1910-1912	In	_	_	_	_
13-2	1913-1916	the	time[106]	new[106]	_	_
13-3	1917-1924	morning	time[106]	new[106]	_	_
13-4	1925-1926	,	_	_	_	_
13-5	1927-1931	when	_	_	_	_
13-6	1932-1943	ketogenesis	substance	new	_	_
13-7	1944-1946	is	_	_	_	_
13-8	1947-1951	high	_	_	_	_
13-9	1952-1955	due	_	_	_	_
13-10	1956-1958	to	_	_	_	_
13-11	1959-1968	overnight	time|event[109]	new|new[109]	_	_
13-12	1969-1976	fasting	event[109]	new[109]	_	_
13-13	1977-1978	,	_	_	_	_
13-14	1979-1991	correlations	abstract	new	_	_
13-15	1992-1996	were	_	_	_	_
13-16	1997-2000	low	_	_	_	_
13-17	2001-2002	,	_	_	_	_
13-18	2003-2007	most	_	_	_	_
13-19	2008-2016	probably	_	_	_	_
13-20	2017-2020	due	_	_	_	_
13-21	2021-2023	to	_	_	_	_
13-22	2024-2026	an	abstract[112]	new[112]	_	_
13-23	2027-2035	additive	person|abstract[112]	new|new[112]	_	_
13-24	2036-2042	effect	abstract[112]	new[112]	_	_
13-25	2043-2045	of	abstract[112]	new[112]	_	_
13-26	2046-2055	lipolysis	abstract[112]|substance	new[112]|giv	coref	14-14
13-27	2056-2059	and	abstract[112]	new[112]	_	_
13-28	2060-2070	glycolysis	abstract[112]|substance	new[112]|giv	_	_
13-29	2071-2073	on	abstract[112]	new[112]	_	_
13-30	2074-2077	the	abstract[112]|event[115]	new[112]|new[115]	_	_
13-31	2078-2087	formation	abstract[112]|event[115]	new[112]|new[115]	_	_
13-32	2088-2090	of	abstract[112]|event[115]	new[112]|new[115]	_	_
13-33	2091-2098	acetone	abstract[112]|event[115]|substance	new[112]|new[115]|giv	coref	15-7
13-34	2099-2100	.	_	_	_	_

#Text=Correlation improved markedly after a moderate intake of carbohydrates and insulin-related inhibition of lipolysis .
14-1	2101-2112	Correlation	abstract	new	coref	15-5[124_0]
14-2	2113-2121	improved	_	_	_	_
14-3	2122-2130	markedly	_	_	_	_
14-4	2131-2136	after	_	_	_	_
14-5	2137-2138	a	event[118]|event[119]	giv[118]|giv[119]	coref	29-24[267_118]
14-6	2139-2147	moderate	event[118]|event[119]	giv[118]|giv[119]	_	_
14-7	2148-2154	intake	event[118]|event[119]	giv[118]|giv[119]	_	_
14-8	2155-2157	of	event[118]|event[119]	giv[118]|giv[119]	_	_
14-9	2158-2171	carbohydrates	event[118]|event[119]|substance	giv[118]|giv[119]|new	coref	28-35
14-10	2172-2175	and	event[119]	giv[119]	_	_
14-11	2176-2191	insulin-related	event[119]|event[121]	giv[119]|new[121]	_	_
14-12	2192-2202	inhibition	event[119]|event[121]	giv[119]|new[121]	_	_
14-13	2203-2205	of	event[119]|event[121]	giv[119]|new[121]	_	_
14-14	2206-2215	lipolysis	event[119]|event[121]|substance	giv[119]|new[121]|giv	_	_
14-15	2216-2217	.	_	_	_	_

#Text=In the afternoon , correlation between acetone and blood glucose remained low .
15-1	2218-2220	In	_	_	_	_
15-2	2221-2224	the	time[123]	new[123]	_	_
15-3	2225-2234	afternoon	time[123]	new[123]	_	_
15-4	2235-2236	,	_	_	_	_
15-5	2237-2248	correlation	abstract[124]	giv[124]	ana	16-1[0_124]
15-6	2249-2256	between	abstract[124]	giv[124]	_	_
15-7	2257-2264	acetone	abstract[124]|substance	giv[124]|giv	coref	17-6
15-8	2265-2268	and	abstract[124]	giv[124]	_	_
15-9	2269-2274	blood	abstract[124]|substance|substance[127]	giv[124]|giv|giv[127]	coref|coref	17-8|17-8[133_127]
15-10	2275-2282	glucose	abstract[124]|substance[127]	giv[124]|giv[127]	_	_
15-11	2283-2291	remained	_	_	_	_
15-12	2292-2295	low	_	_	_	_
15-13	2296-2297	.	_	_	_	_

#Text=This was most probably due to postprandial hyperglycemia .
16-1	2298-2302	This	abstract	giv	coref	17-3[130_0]
16-2	2303-2306	was	_	_	_	_
16-3	2307-2311	most	_	_	_	_
16-4	2312-2320	probably	_	_	_	_
16-5	2321-2324	due	_	_	_	_
16-6	2325-2327	to	_	_	_	_
16-7	2328-2340	postprandial	abstract[129]	new[129]	coref	25-19[226_129]
16-8	2341-2354	hyperglycemia	abstract[129]	new[129]	_	_
16-9	2355-2356	.	_	_	_	_

#Text=Thus , a correlation of acetone with blood glucose is difficult even under healthy conditions and the time-resolved calculation of the correlation coefficients in our study strengthen this observation .
17-1	2357-2361	Thus	_	_	_	_
17-2	2362-2363	,	_	_	_	_
17-3	2364-2365	a	abstract[130]	giv[130]	coref	17-22[0_130]
17-4	2366-2377	correlation	abstract[130]	giv[130]	_	_
17-5	2378-2380	of	abstract[130]	giv[130]	_	_
17-6	2381-2388	acetone	abstract[130]|substance	giv[130]|giv	coref	18-15
17-7	2389-2393	with	abstract[130]	giv[130]	_	_
17-8	2394-2399	blood	abstract[130]|substance|substance[133]	giv[130]|giv|giv[133]	coref	23-12
17-9	2400-2407	glucose	abstract[130]|substance[133]	giv[130]|giv[133]	_	_
17-10	2408-2410	is	_	_	_	_
17-11	2411-2420	difficult	_	_	_	_
17-12	2421-2425	even	abstract[134]	giv[134]	coref	23-2[194_134]
17-13	2426-2431	under	abstract[134]	giv[134]	_	_
17-14	2432-2439	healthy	abstract[134]	giv[134]	_	_
17-15	2440-2450	conditions	abstract[134]	giv[134]	_	_
17-16	2451-2454	and	_	_	_	_
17-17	2455-2458	the	abstract[135]	new[135]	_	_
17-18	2459-2472	time-resolved	abstract[135]	new[135]	_	_
17-19	2473-2484	calculation	abstract[135]	new[135]	_	_
17-20	2485-2487	of	abstract[135]	new[135]	_	_
17-21	2488-2491	the	abstract[135]|abstract[137]	new[135]|new[137]	coref	19-23[155_137]
17-22	2492-2503	correlation	abstract[135]|abstract|abstract[137]	new[135]|giv|new[137]	coref	19-26
17-23	2504-2516	coefficients	abstract[135]|abstract[137]	new[135]|new[137]	_	_
17-24	2517-2519	in	abstract[135]|abstract[137]	new[135]|new[137]	_	_
17-25	2520-2523	our	abstract[135]|abstract[137]|person|abstract[139]	new[135]|new[137]|giv|giv[139]	_	_
17-26	2524-2529	study	abstract[135]|abstract[137]|abstract[139]	new[135]|new[137]|giv[139]	_	_
17-27	2530-2540	strengthen	_	_	_	_
17-28	2541-2545	this	abstract[140]	new[140]	_	_
17-29	2546-2557	observation	abstract[140]	new[140]	_	_
17-30	2558-2559	.	_	_	_	_

#Text=Furthermore , the impact of hepatic alcohol dehydrogenase , i.e. , the reduction of acetone to isopropanol , has to be considered .
18-1	2560-2571	Furthermore	_	_	_	_
18-2	2572-2573	,	_	_	_	_
18-3	2574-2577	the	abstract[141]	new[141]	_	_
18-4	2578-2584	impact	abstract[141]	new[141]	_	_
18-5	2585-2587	of	abstract[141]	new[141]	_	_
18-6	2588-2595	hepatic	abstract[141]|event[143]	new[141]|new[143]	_	_
18-7	2596-2603	alcohol	abstract[141]|substance|event[143]	new[141]|new|new[143]	_	_
18-8	2604-2617	dehydrogenase	abstract[141]|event[143]	new[141]|new[143]	_	_
18-9	2618-2619	,	_	_	_	_
18-10	2620-2624	i.e.	event[144]	new[144]	_	_
18-11	2625-2626	,	event[144]	new[144]	_	_
18-12	2627-2630	the	event[144]	new[144]	_	_
18-13	2631-2640	reduction	event[144]	new[144]	_	_
18-14	2641-2643	of	event[144]	new[144]	_	_
18-15	2644-2651	acetone	event[144]|substance	new[144]|giv	coref	19-33
18-16	2652-2654	to	event[144]	new[144]	_	_
18-17	2655-2666	isopropanol	event[144]|substance	new[144]|giv	coref	19-7[149_0]
18-18	2667-2668	,	_	_	_	_
18-19	2669-2672	has	_	_	_	_
18-20	2673-2675	to	_	_	_	_
18-21	2676-2678	be	_	_	_	_
18-22	2679-2689	considered	_	_	_	_
18-23	2690-2691	.	_	_	_	_

#Text=In fact , T1DM patients exhaled significantly more isopropanol than their healthy peers and both , the diurnal profile as well as the time resolved correlation coefficients , closely resembled that of acetone .
19-1	2692-2694	In	_	_	_	_
19-2	2695-2699	fact	_	_	_	_
19-3	2700-2701	,	_	_	_	_
19-4	2702-2706	T1DM	abstract|person[148]	giv|giv[148]	ana|coref	19-11[0_148]|20-8
19-5	2707-2715	patients	person[148]	giv[148]	_	_
19-6	2716-2723	exhaled	_	_	_	_
19-7	2724-2737	significantly	substance[149]	giv[149]	ana	19-31[156_149]
19-8	2738-2742	more	substance[149]	giv[149]	_	_
19-9	2743-2754	isopropanol	substance[149]	giv[149]	_	_
19-10	2755-2759	than	_	_	_	_
19-11	2760-2765	their	person|person[151]	giv|new[151]	coref	20-8[161_0]
19-12	2766-2773	healthy	person[151]	new[151]	_	_
19-13	2774-2779	peers	person[151]	new[151]	_	_
19-14	2780-2783	and	_	_	_	_
19-15	2784-2788	both	_	_	_	_
19-16	2789-2790	,	_	_	_	_
19-17	2791-2794	the	abstract[152]	new[152]	_	_
19-18	2795-2802	diurnal	abstract[152]	new[152]	_	_
19-19	2803-2810	profile	abstract[152]	new[152]	_	_
19-20	2811-2813	as	_	_	_	_
19-21	2814-2818	well	_	_	_	_
19-22	2819-2821	as	_	_	_	_
19-23	2822-2825	the	abstract[155]	giv[155]	_	_
19-24	2826-2830	time	time|abstract[155]	new|giv[155]	_	_
19-25	2831-2839	resolved	abstract[155]	giv[155]	_	_
19-26	2840-2851	correlation	abstract|abstract[155]	giv|giv[155]	coref	28-2[246_0]
19-27	2852-2864	coefficients	abstract[155]	giv[155]	_	_
19-28	2865-2866	,	_	_	_	_
19-29	2867-2874	closely	_	_	_	_
19-30	2875-2884	resembled	_	_	_	_
19-31	2885-2889	that	substance[156]	giv[156]	_	_
19-32	2890-2892	of	substance[156]	giv[156]	_	_
19-33	2893-2900	acetone	substance[156]|substance	giv[156]|giv	coref	20-13
19-34	2901-2902	.	_	_	_	_

#Text=Thus , activation of this pathway in T1DM patients may attribute to acetone elimination and indicate metabolic adaptation .
20-1	2903-2907	Thus	_	_	_	_
20-2	2908-2909	,	_	_	_	_
20-3	2910-2920	activation	event[158]	new[158]	_	_
20-4	2921-2923	of	event[158]	new[158]	_	_
20-5	2924-2928	this	event[158]|abstract[159]	new[158]|giv[159]	_	_
20-6	2929-2936	pathway	event[158]|abstract[159]	new[158]|giv[159]	_	_
20-7	2937-2939	in	event[158]	new[158]	_	_
20-8	2940-2944	T1DM	event[158]|abstract|person[161]	new[158]|giv|giv[161]	coref|coref	21-25|21-25[174_161]
20-9	2945-2953	patients	event[158]|person[161]	new[158]|giv[161]	_	_
20-10	2954-2957	may	_	_	_	_
20-11	2958-2967	attribute	_	_	_	_
20-12	2968-2970	to	_	_	_	_
20-13	2971-2978	acetone	substance|abstract[163]	giv|new[163]	_	_
20-14	2979-2990	elimination	abstract[163]	new[163]	_	_
20-15	2991-2994	and	_	_	_	_
20-16	2995-3003	indicate	_	_	_	_
20-17	3004-3013	metabolic	abstract[164]	new[164]	_	_
20-18	3014-3024	adaptation	abstract[164]	new[164]	_	_
20-19	3025-3026	.	_	_	_	_

#Text=The shape of the normalized diurnal profiles of glucose , insulin , glucagon , lipids , leptin , and slepR are fairly comparable in T1DM patients and healthy controls , but differ with respect to slope and inter-individual variability , i.e. , changes over time are faster in controls while inter-individual variability is much greater in T1DM patients .
21-1	3027-3030	The	abstract[165]	new[165]	_	_
21-2	3031-3036	shape	abstract[165]	new[165]	_	_
21-3	3037-3039	of	abstract[165]	new[165]	_	_
21-4	3040-3043	the	abstract[165]|abstract[166]	new[165]|new[166]	coref	28-13[252_166]
21-5	3044-3054	normalized	abstract[165]|abstract[166]	new[165]|new[166]	_	_
21-6	3055-3062	diurnal	abstract[165]|abstract[166]	new[165]|new[166]	_	_
21-7	3063-3071	profiles	abstract[165]|abstract[166]	new[165]|new[166]	_	_
21-8	3072-3074	of	abstract[165]|abstract[166]	new[165]|new[166]	_	_
21-9	3075-3082	glucose	abstract[165]|abstract[166]|substance	new[165]|new[166]|new	coref	22-29
21-10	3083-3084	,	abstract[165]|abstract[166]	new[165]|new[166]	_	_
21-11	3085-3092	insulin	abstract[165]|abstract[166]|substance	new[165]|new[166]|new	coref	22-17
21-12	3093-3094	,	abstract[165]|abstract[166]	new[165]|new[166]	_	_
21-13	3095-3103	glucagon	abstract[165]|abstract[166]|substance	new[165]|new[166]|new	coref	22-31
21-14	3104-3105	,	abstract[165]|abstract[166]	new[165]|new[166]	_	_
21-15	3106-3112	lipids	abstract[165]|abstract[166]|substance	new[165]|new[166]|new	_	_
21-16	3113-3114	,	abstract[165]|abstract[166]	new[165]|new[166]	_	_
21-17	3115-3121	leptin	abstract[165]|abstract[166]|substance	new[165]|new[166]|new	_	_
21-18	3122-3123	,	abstract[165]|abstract[166]	new[165]|new[166]	_	_
21-19	3124-3127	and	abstract[165]|abstract[166]	new[165]|new[166]	_	_
21-20	3128-3133	slepR	abstract[165]|abstract[166]|abstract	new[165]|new[166]|new	_	_
21-21	3134-3137	are	_	_	_	_
21-22	3138-3144	fairly	_	_	_	_
21-23	3145-3155	comparable	_	_	_	_
21-24	3156-3158	in	_	_	_	_
21-25	3159-3163	T1DM	abstract|person[174]|person[175]	giv|giv[174]|giv[175]	coref|coref|coref	21-57|21-57[183_174]|30-29[281_175]
21-26	3164-3172	patients	person[174]|person[175]	giv[174]|giv[175]	_	_
21-27	3173-3176	and	person[175]	giv[175]	_	_
21-28	3177-3184	healthy	person[175]|event[176]	giv[175]|giv[176]	coref	21-49[0_176]
21-29	3185-3193	controls	person[175]|event[176]	giv[175]|giv[176]	_	_
21-30	3194-3195	,	_	_	_	_
21-31	3196-3199	but	_	_	_	_
21-32	3200-3206	differ	_	_	_	_
21-33	3207-3211	with	_	_	_	_
21-34	3212-3219	respect	_	_	_	_
21-35	3220-3222	to	_	_	_	_
21-36	3223-3228	slope	abstract	new	_	_
21-37	3229-3232	and	_	_	_	_
21-38	3233-3249	inter-individual	abstract[178]	new[178]	coref	21-51[181_178]
21-39	3250-3261	variability	abstract[178]	new[178]	_	_
21-40	3262-3263	,	_	_	_	_
21-41	3264-3268	i.e.	_	_	_	_
21-42	3269-3270	,	_	_	_	_
21-43	3271-3278	changes	abstract[179]	new[179]	_	_
21-44	3279-3283	over	abstract[179]	new[179]	_	_
21-45	3284-3288	time	abstract[179]	new[179]	_	_
21-46	3289-3292	are	_	_	_	_
21-47	3293-3299	faster	_	_	_	_
21-48	3300-3302	in	_	_	_	_
21-49	3303-3311	controls	event	giv	coref	30-32
21-50	3312-3317	while	_	_	_	_
21-51	3318-3334	inter-individual	abstract[181]	giv[181]	ana	22-1[0_181]
21-52	3335-3346	variability	abstract[181]	giv[181]	_	_
21-53	3347-3349	is	_	_	_	_
21-54	3350-3354	much	_	_	_	_
21-55	3355-3362	greater	_	_	_	_
21-56	3363-3365	in	_	_	_	_
21-57	3366-3370	T1DM	abstract|person[183]	giv|giv[183]	coref|coref	25-5|25-5[222_183]
21-58	3371-3379	patients	person[183]	giv[183]	_	_
21-59	3380-3381	.	_	_	_	_

#Text=This might , at least in part , be due to the limited abilities of pharmaceutical insulin preparations to mimic the physiological interplay between insulin-induced cellular uptake of glucose and glucagon secretion .
22-1	3382-3386	This	abstract	giv	_	_
22-2	3387-3392	might	_	_	_	_
22-3	3393-3394	,	_	_	_	_
22-4	3395-3397	at	_	_	_	_
22-5	3398-3403	least	_	_	_	_
22-6	3404-3406	in	_	_	_	_
22-7	3407-3411	part	_	_	_	_
22-8	3412-3413	,	_	_	_	_
22-9	3414-3416	be	_	_	_	_
22-10	3417-3420	due	_	_	_	_
22-11	3421-3423	to	_	_	_	_
22-12	3424-3427	the	abstract[185]	new[185]	_	_
22-13	3428-3435	limited	abstract[185]	new[185]	_	_
22-14	3436-3445	abilities	abstract[185]	new[185]	_	_
22-15	3446-3448	of	abstract[185]	new[185]	_	_
22-16	3449-3463	pharmaceutical	abstract[185]|substance[187]	new[185]|new[187]	_	_
22-17	3464-3471	insulin	abstract[185]|substance|substance[187]	new[185]|giv|new[187]	coref	23-5
22-18	3472-3484	preparations	abstract[185]|substance[187]	new[185]|new[187]	_	_
22-19	3485-3487	to	abstract[185]	new[185]	_	_
22-20	3488-3493	mimic	abstract[185]	new[185]	_	_
22-21	3494-3497	the	abstract[185]|abstract[188]	new[185]|new[188]	_	_
22-22	3498-3511	physiological	abstract[185]|abstract[188]	new[185]|new[188]	_	_
22-23	3512-3521	interplay	abstract[185]|abstract[188]	new[185]|new[188]	_	_
22-24	3522-3529	between	abstract[185]|abstract[188]	new[185]|new[188]	_	_
22-25	3530-3545	insulin-induced	abstract[185]|abstract[188]|abstract[189]|abstract[190]	new[185]|new[188]|new[189]|new[190]	coref|coref	23-18[200_189]|23-18[201_190]
22-26	3546-3554	cellular	abstract[185]|abstract[188]|abstract[189]|abstract[190]	new[185]|new[188]|new[189]|new[190]	_	_
22-27	3555-3561	uptake	abstract[185]|abstract[188]|abstract[189]|abstract[190]	new[185]|new[188]|new[189]|new[190]	_	_
22-28	3562-3564	of	abstract[185]|abstract[188]|abstract[189]|abstract[190]	new[185]|new[188]|new[189]|new[190]	_	_
22-29	3565-3572	glucose	abstract[185]|abstract[188]|abstract[189]|abstract[190]|substance	new[185]|new[188]|new[189]|new[190]|giv	coref	23-12[197_0]
22-30	3573-3576	and	abstract[185]|abstract[188]|abstract[190]	new[185]|new[188]|new[190]	_	_
22-31	3577-3585	glucagon	abstract[185]|abstract[188]|abstract[190]|substance|substance[193]	new[185]|new[188]|new[190]|giv|new[193]	coref|coref	23-25|23-24[204_193]
22-32	3586-3595	secretion	abstract[185]|abstract[188]|abstract[190]|substance[193]	new[185]|new[188]|new[190]|new[193]	_	_
22-33	3596-3597	.	_	_	_	_

#Text=Under physiological conditions , insulin is secreted in response to increasing blood glucose levels and by inducing cellular glucose uptake and inhibition of pancreatic glucagon secretion at the same time it contributes to maintenance of glucose homeostasis .
23-1	3598-3603	Under	_	_	_	_
23-2	3604-3617	physiological	abstract[194]	giv[194]	_	_
23-3	3618-3628	conditions	abstract[194]	giv[194]	_	_
23-4	3629-3630	,	_	_	_	_
23-5	3631-3638	insulin	substance	giv	coref	24-26
23-6	3639-3641	is	_	_	_	_
23-7	3642-3650	secreted	_	_	_	_
23-8	3651-3653	in	_	_	_	_
23-9	3654-3662	response	_	_	_	_
23-10	3663-3665	to	_	_	_	_
23-11	3666-3676	increasing	abstract[198]	giv[198]	coref	27-14[236_198]
23-12	3677-3682	blood	substance|substance[197]|abstract[198]	giv|giv[197]|giv[198]	coref|coref	23-19[0_197]|24-10
23-13	3683-3690	glucose	substance[197]|abstract[198]	giv[197]|giv[198]	_	_
23-14	3691-3697	levels	abstract[198]	giv[198]	_	_
23-15	3698-3701	and	_	_	_	_
23-16	3702-3704	by	_	_	_	_
23-17	3705-3713	inducing	_	_	_	_
23-18	3714-3722	cellular	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
23-19	3723-3730	glucose	substance|abstract[200]|abstract[201]	giv|giv[200]|giv[201]	coref	23-36
23-20	3731-3737	uptake	abstract[200]|abstract[201]	giv[200]|giv[201]	_	_
23-21	3738-3741	and	abstract[201]	giv[201]	_	_
23-22	3742-3752	inhibition	abstract[201]|person[202]	giv[201]|new[202]	_	_
23-23	3753-3755	of	abstract[201]|person[202]	giv[201]|new[202]	_	_
23-24	3756-3766	pancreatic	abstract[201]|person[202]|substance[204]	giv[201]|new[202]|giv[204]	ana	23-31[0_204]
23-25	3767-3775	glucagon	abstract[201]|person[202]|substance|substance[204]	giv[201]|new[202]|giv|giv[204]	coref	24-7
23-26	3776-3785	secretion	abstract[201]|person[202]|substance[204]	giv[201]|new[202]|giv[204]	_	_
23-27	3786-3788	at	_	_	_	_
23-28	3789-3792	the	time[205]	giv[205]	_	_
23-29	3793-3797	same	time[205]	giv[205]	_	_
23-30	3798-3802	time	time[205]	giv[205]	_	_
23-31	3803-3805	it	substance	giv	_	_
23-32	3806-3817	contributes	_	_	_	_
23-33	3818-3820	to	_	_	_	_
23-34	3821-3832	maintenance	event[207]	new[207]	_	_
23-35	3833-3835	of	event[207]	new[207]	_	_
23-36	3836-3843	glucose	event[207]|substance|abstract[209]	new[207]|giv|new[209]	coref	24-18
23-37	3844-3855	homeostasis	event[207]|abstract[209]	new[207]|new[209]	_	_
23-38	3856-3857	.	_	_	_	_

#Text=Thus , in healthy individuals , glucagon concentration in blood remains constant as long as the blood glucose concentration stays within the normal range and insulin concentrations peak after meals .
24-1	3858-3862	Thus	_	_	_	_
24-2	3863-3864	,	_	_	_	_
24-3	3865-3867	in	_	_	_	_
24-4	3868-3875	healthy	animal[210]	new[210]	_	_
24-5	3876-3887	individuals	animal[210]	new[210]	_	_
24-6	3888-3889	,	_	_	_	_
24-7	3890-3898	glucagon	substance|abstract[212]	giv|new[212]	coref|coref	24-16[216_212]|25-7
24-8	3899-3912	concentration	abstract[212]	new[212]	_	_
24-9	3913-3915	in	abstract[212]	new[212]	_	_
24-10	3916-3921	blood	abstract[212]|substance	new[212]|giv	coref	24-17
24-11	3922-3929	remains	_	_	_	_
24-12	3930-3938	constant	_	_	_	_
24-13	3939-3941	as	_	_	_	_
24-14	3942-3946	long	_	_	_	_
24-15	3947-3949	as	_	_	_	_
24-16	3950-3953	the	abstract[216]	giv[216]	coref	28-14[0_216]
24-17	3954-3959	blood	substance|abstract[216]	giv|giv[216]	_	_
24-18	3960-3967	glucose	substance|abstract[216]	giv|giv[216]	_	_
24-19	3968-3981	concentration	abstract[216]	giv[216]	_	_
24-20	3982-3987	stays	_	_	_	_
24-21	3988-3994	within	_	_	_	_
24-22	3995-3998	the	abstract[217]	new[217]	_	_
24-23	3999-4005	normal	abstract[217]	new[217]	_	_
24-24	4006-4011	range	abstract[217]	new[217]	_	_
24-25	4012-4015	and	_	_	_	_
24-26	4016-4023	insulin	substance|abstract[219]	giv|giv[219]	coref|coref	25-7[224_219]|27-30
24-27	4024-4038	concentrations	abstract[219]	giv[219]	_	_
24-28	4039-4043	peak	_	_	_	_
24-29	4044-4049	after	_	_	_	_
24-30	4050-4055	meals	event	giv	coref	25-12[225_0]
24-31	4056-4057	.	_	_	_	_

#Text=In contrast , in T1DM patients glucagon concentrations remain partially elevated even after meals and most likely aggravate postprandial hyperglycemia .
25-1	4058-4060	In	_	_	_	_
25-2	4061-4069	contrast	_	_	_	_
25-3	4070-4071	,	_	_	_	_
25-4	4072-4074	in	_	_	_	_
25-5	4075-4079	T1DM	abstract|person[222]	giv|giv[222]	coref|coref	27-49|27-48[245_222]
25-6	4080-4088	patients	person[222]	giv[222]	_	_
25-7	4089-4097	glucagon	substance|abstract[224]	giv|giv[224]	coref	31-16[287_224]
25-8	4098-4112	concentrations	abstract[224]	giv[224]	_	_
25-9	4113-4119	remain	_	_	_	_
25-10	4120-4129	partially	_	_	_	_
25-11	4130-4138	elevated	_	_	_	_
25-12	4139-4143	even	event[225]	giv[225]	_	_
25-13	4144-4149	after	event[225]	giv[225]	_	_
25-14	4150-4155	meals	event[225]	giv[225]	_	_
25-15	4156-4159	and	_	_	_	_
25-16	4160-4164	most	_	_	_	_
25-17	4165-4171	likely	_	_	_	_
25-18	4172-4181	aggravate	_	_	_	_
25-19	4182-4194	postprandial	abstract[226]	giv[226]	coref	30-14[276_226]
25-20	4195-4208	hyperglycemia	abstract[226]	giv[226]	_	_
25-21	4209-4210	.	_	_	_	_

#Text=The latter , especially in concert with dyslipidemia is considered as a relevant contributor to the overall increased risk for the development of cardiovascular disease .
26-1	4211-4214	The	_	_	_	_
26-2	4215-4221	latter	_	_	_	_
26-3	4222-4223	,	_	_	_	_
26-4	4224-4234	especially	_	_	_	_
26-5	4235-4237	in	_	_	_	_
26-6	4238-4245	concert	_	_	_	_
26-7	4246-4250	with	_	_	_	_
26-8	4251-4263	dyslipidemia	abstract	new	_	_
26-9	4264-4266	is	_	_	_	_
26-10	4267-4277	considered	_	_	_	_
26-11	4278-4280	as	_	_	_	_
26-12	4281-4282	a	abstract[228]	new[228]	_	_
26-13	4283-4291	relevant	abstract[228]	new[228]	_	_
26-14	4292-4303	contributor	abstract[228]	new[228]	_	_
26-15	4304-4306	to	abstract[228]	new[228]	_	_
26-16	4307-4310	the	abstract[228]|abstract[229]	new[228]|new[229]	_	_
26-17	4311-4318	overall	abstract[228]|abstract[229]	new[228]|new[229]	_	_
26-18	4319-4328	increased	abstract[228]|abstract[229]	new[228]|new[229]	_	_
26-19	4329-4333	risk	abstract[228]|abstract[229]	new[228]|new[229]	_	_
26-20	4334-4337	for	abstract[228]|abstract[229]	new[228]|new[229]	_	_
26-21	4338-4341	the	abstract[228]|abstract[229]|event[230]	new[228]|new[229]|new[230]	_	_
26-22	4342-4353	development	abstract[228]|abstract[229]|event[230]	new[228]|new[229]|new[230]	_	_
26-23	4354-4356	of	abstract[228]|abstract[229]|event[230]	new[228]|new[229]|new[230]	_	_
26-24	4357-4371	cardiovascular	abstract[228]|abstract[229]|event[230]|abstract[231]	new[228]|new[229]|new[230]|new[231]	_	_
26-25	4372-4379	disease	abstract[228]|abstract[229]|event[230]|abstract[231]	new[228]|new[229]|new[230]|new[231]	_	_
26-26	4380-4381	.	_	_	_	_

#Text=On the one hand , poor glycemic control is likely to result in elevated cholesterol and triglyceride levels , on the other hand , peripheral hyperinsulinemia secondary to subcutaneous insulin administration contribute to qualitative abnormalities of lipid metabolism as well and this has recently been shown in young T1DM patients .
27-1	4382-4384	On	_	_	_	_
27-2	4385-4388	the	_	_	_	_
27-3	4389-4392	one	_	_	_	_
27-4	4393-4397	hand	_	_	_	_
27-5	4398-4399	,	_	_	_	_
27-6	4400-4404	poor	abstract[233]	new[233]	_	_
27-7	4405-4413	glycemic	abstract|abstract[233]	new|new[233]	_	_
27-8	4414-4421	control	abstract[233]	new[233]	_	_
27-9	4422-4424	is	_	_	_	_
27-10	4425-4431	likely	_	_	_	_
27-11	4432-4434	to	_	_	_	_
27-12	4435-4441	result	_	_	_	_
27-13	4442-4444	in	_	_	_	_
27-14	4445-4453	elevated	abstract[236]	giv[236]	_	_
27-15	4454-4465	cholesterol	substance|abstract[236]	new|giv[236]	_	_
27-16	4466-4469	and	abstract[236]	giv[236]	_	_
27-17	4470-4482	triglyceride	abstract|abstract[236]	new|giv[236]	_	_
27-18	4483-4489	levels	abstract[236]	giv[236]	_	_
27-19	4490-4491	,	_	_	_	_
27-20	4492-4494	on	_	_	_	_
27-21	4495-4498	the	_	_	_	_
27-22	4499-4504	other	_	_	_	_
27-23	4505-4509	hand	_	_	_	_
27-24	4510-4511	,	_	_	_	_
27-25	4512-4522	peripheral	abstract[237]	new[237]	_	_
27-26	4523-4539	hyperinsulinemia	abstract[237]	new[237]	_	_
27-27	4540-4549	secondary	abstract[237]	new[237]	_	_
27-28	4550-4552	to	_	_	_	_
27-29	4553-4565	subcutaneous	event[239]	new[239]	ana	27-42[0_239]
27-30	4566-4573	insulin	substance|event[239]	giv|new[239]	_	_
27-31	4574-4588	administration	event[239]	new[239]	_	_
27-32	4589-4599	contribute	_	_	_	_
27-33	4600-4602	to	_	_	_	_
27-34	4603-4614	qualitative	abstract[240]	new[240]	_	_
27-35	4615-4628	abnormalities	abstract[240]	new[240]	_	_
27-36	4629-4631	of	abstract[240]	new[240]	_	_
27-37	4632-4637	lipid	abstract[240]|object|abstract[242]	new[240]|new|new[242]	_	_
27-38	4638-4648	metabolism	abstract[240]|abstract[242]	new[240]|new[242]	_	_
27-39	4649-4651	as	_	_	_	_
27-40	4652-4656	well	_	_	_	_
27-41	4657-4660	and	_	_	_	_
27-42	4661-4665	this	event	giv	_	_
27-43	4666-4669	has	_	_	_	_
27-44	4670-4678	recently	_	_	_	_
27-45	4679-4683	been	_	_	_	_
27-46	4684-4689	shown	_	_	_	_
27-47	4690-4692	in	_	_	_	_
27-48	4693-4698	young	person[245]	giv[245]	coref	30-29[280_245]
27-49	4699-4703	T1DM	abstract|person[245]	giv|giv[245]	coref	30-29
27-50	4704-4712	patients	person[245]	giv[245]	_	_
27-51	4713-4714	.	_	_	_	_

#Text=Albeit no clear correlation between breath ethanol and serum triglycerides exists , the concentration profiles were quite similar , especially in the second half of the examination period , i.e. , after challenge with carbohydrates ( pasta ) at lunch .
28-1	4715-4721	Albeit	_	_	_	_
28-2	4722-4724	no	abstract[246]	giv[246]	_	_
28-3	4725-4730	clear	abstract[246]	giv[246]	_	_
28-4	4731-4742	correlation	abstract[246]	giv[246]	_	_
28-5	4743-4750	between	abstract[246]	giv[246]	_	_
28-6	4751-4757	breath	abstract[246]|abstract|substance[248]	giv[246]|giv|new[248]	coref|coref	29-1[260_248]|29-18
28-7	4758-4765	ethanol	abstract[246]|substance[248]	giv[246]|new[248]	_	_
28-8	4766-4769	and	abstract[246]	giv[246]	_	_
28-9	4770-4775	serum	abstract[246]|substance|substance[250]	giv[246]|new|new[250]	_	_
28-10	4776-4789	triglycerides	abstract[246]|substance[250]	giv[246]|new[250]	_	_
28-11	4790-4796	exists	_	_	_	_
28-12	4797-4798	,	_	_	_	_
28-13	4799-4802	the	abstract[252]	giv[252]	_	_
28-14	4803-4816	concentration	abstract|abstract[252]	giv|giv[252]	_	_
28-15	4817-4825	profiles	abstract[252]	giv[252]	_	_
28-16	4826-4830	were	_	_	_	_
28-17	4831-4836	quite	_	_	_	_
28-18	4837-4844	similar	_	_	_	_
28-19	4845-4846	,	_	_	_	_
28-20	4847-4857	especially	time[253]	new[253]	coref	28-26[255_253]
28-21	4858-4860	in	time[253]	new[253]	_	_
28-22	4861-4864	the	time[253]	new[253]	_	_
28-23	4865-4871	second	time[253]	new[253]	_	_
28-24	4872-4876	half	time[253]	new[253]	_	_
28-25	4877-4879	of	time[253]	new[253]	_	_
28-26	4880-4883	the	time[253]|time[255]	new[253]|giv[255]	_	_
28-27	4884-4895	examination	time[253]|event|time[255]	new[253]|new|giv[255]	_	_
28-28	4896-4902	period	time[253]|time[255]	new[253]|giv[255]	_	_
28-29	4903-4904	,	_	_	_	_
28-30	4905-4909	i.e.	event[256]	new[256]	_	_
28-31	4910-4911	,	event[256]	new[256]	_	_
28-32	4912-4917	after	event[256]	new[256]	_	_
28-33	4918-4927	challenge	event[256]	new[256]	_	_
28-34	4928-4932	with	event[256]	new[256]	_	_
28-35	4933-4946	carbohydrates	event[256]|substance	new[256]|giv	appos	28-37
28-36	4947-4948	(	event[256]	new[256]	_	_
28-37	4949-4954	pasta	event[256]|substance	new[256]|giv	coref	29-14
28-38	4955-4956	)	event[256]	new[256]	_	_
28-39	4957-4959	at	event[256]	new[256]	_	_
28-40	4960-4965	lunch	event[256]|event	new[256]|new	coref	30-6
28-41	4966-4967	.	_	_	_	_

#Text=Endogenous ethanol is supposed to originate from intestinal bacterial activity via fermentation of carbohydrates , i.e. , breath ethanol increase is due to the intake with subsequent digestion of carbohydrates and the intestinal microbiota .
29-1	4968-4978	Endogenous	substance[260]	giv[260]	coref	29-19[0_260]
29-2	4979-4986	ethanol	substance[260]	giv[260]	_	_
29-3	4987-4989	is	_	_	_	_
29-4	4990-4998	supposed	_	_	_	_
29-5	4999-5001	to	_	_	_	_
29-6	5002-5011	originate	_	_	_	_
29-7	5012-5016	from	_	_	_	_
29-8	5017-5027	intestinal	event[261]	new[261]	_	_
29-9	5028-5037	bacterial	event[261]	new[261]	_	_
29-10	5038-5046	activity	event[261]	new[261]	_	_
29-11	5047-5050	via	_	_	_	_
29-12	5051-5063	fermentation	abstract[262]	new[262]	_	_
29-13	5064-5066	of	abstract[262]	new[262]	_	_
29-14	5067-5080	carbohydrates	abstract[262]|substance	new[262]|giv	coref	29-30
29-15	5081-5082	,	_	_	_	_
29-16	5083-5087	i.e.	_	_	_	_
29-17	5088-5089	,	_	_	_	_
29-18	5090-5096	breath	abstract|event[266]	giv|new[266]	coref	31-7[284_266]
29-19	5097-5104	ethanol	substance|event[266]	giv|new[266]	coref	31-13[285_0]
29-20	5105-5113	increase	event[266]	new[266]	_	_
29-21	5114-5116	is	_	_	_	_
29-22	5117-5120	due	_	_	_	_
29-23	5121-5123	to	_	_	_	_
29-24	5124-5127	the	event[267]	giv[267]	coref	30-2[273_267]
29-25	5128-5134	intake	event[267]	giv[267]	_	_
29-26	5135-5139	with	event[267]	giv[267]	_	_
29-27	5140-5150	subsequent	event[267]|event[268]	giv[267]|new[268]	_	_
29-28	5151-5160	digestion	event[267]|event[268]	giv[267]|new[268]	_	_
29-29	5161-5163	of	event[267]|event[268]	giv[267]|new[268]	_	_
29-30	5164-5177	carbohydrates	event[267]|event[268]|substance|substance[270]	giv[267]|new[268]|giv|giv[270]	coref	29-30[270_0]
29-31	5178-5181	and	event[267]|event[268]|substance[270]	giv[267]|new[268]|giv[270]	_	_
29-32	5182-5185	the	event[267]|event[268]|substance[270]|substance[271]	giv[267]|new[268]|giv[270]|new[271]	coref	30-25[278_271]
29-33	5186-5196	intestinal	event[267]|event[268]|substance[270]|substance[271]	giv[267]|new[268]|giv[270]|new[271]	_	_
29-34	5197-5207	microbiota	event[267]|event[268]|substance[270]|substance[271]	giv[267]|new[268]|giv[270]|new[271]	_	_
29-35	5208-5209	.	_	_	_	_

#Text=While the carbohydrate intake at lunch was quite similar in both groups , postprandial hyperglycemia was not and even subtle differences with respect to the intestinal microbiota between T1DM patients and controls have to be considered .
30-1	5210-5215	While	_	_	_	_
30-2	5216-5219	the	event[273]	giv[273]	_	_
30-3	5220-5232	carbohydrate	substance|event[273]	new|giv[273]	_	_
30-4	5233-5239	intake	event[273]	giv[273]	_	_
30-5	5240-5242	at	event[273]	giv[273]	_	_
30-6	5243-5248	lunch	event[273]|event	giv[273]|giv	ana	31-3
30-7	5249-5252	was	_	_	_	_
30-8	5253-5258	quite	_	_	_	_
30-9	5259-5266	similar	_	_	_	_
30-10	5267-5269	in	_	_	_	_
30-11	5270-5274	both	person[275]	new[275]	_	_
30-12	5275-5281	groups	person[275]	new[275]	_	_
30-13	5282-5283	,	_	_	_	_
30-14	5284-5296	postprandial	abstract[276]	giv[276]	_	_
30-15	5297-5310	hyperglycemia	abstract[276]	giv[276]	_	_
30-16	5311-5314	was	_	_	_	_
30-17	5315-5318	not	_	_	_	_
30-18	5319-5322	and	_	_	_	_
30-19	5323-5327	even	abstract[277]	new[277]	_	_
30-20	5328-5334	subtle	abstract[277]	new[277]	_	_
30-21	5335-5346	differences	abstract[277]	new[277]	_	_
30-22	5347-5351	with	abstract[277]	new[277]	_	_
30-23	5352-5359	respect	abstract[277]	new[277]	_	_
30-24	5360-5362	to	abstract[277]	new[277]	_	_
30-25	5363-5366	the	abstract[277]|substance[278]	new[277]|giv[278]	_	_
30-26	5367-5377	intestinal	abstract[277]|substance[278]	new[277]|giv[278]	_	_
30-27	5378-5388	microbiota	abstract[277]|substance[278]	new[277]|giv[278]	_	_
30-28	5389-5396	between	abstract[277]|substance[278]	new[277]|giv[278]	_	_
30-29	5397-5401	T1DM	abstract[277]|substance[278]|abstract|person[280]|person[281]	new[277]|giv[278]|giv|giv[280]|giv[281]	coref|coref	31-21|31-21[289_280]
30-30	5402-5410	patients	abstract[277]|substance[278]|person[280]|person[281]	new[277]|giv[278]|giv[280]|giv[281]	_	_
30-31	5411-5414	and	abstract[277]|substance[278]|person[281]	new[277]|giv[278]|giv[281]	_	_
30-32	5415-5423	controls	abstract[277]|substance[278]|person[281]|event	new[277]|giv[278]|giv[281]|giv	_	_
30-33	5424-5428	have	_	_	_	_
30-34	5429-5431	to	_	_	_	_
30-35	5432-5434	be	_	_	_	_
30-36	5435-5445	considered	_	_	_	_
30-37	5446-5447	.	_	_	_	_

#Text=Altogether , this may have caused a slightly more pronounced increase of postprandial ethanol with higher peak ethanol concentrations in T1DM patients .
31-1	5448-5458	Altogether	_	_	_	_
31-2	5459-5460	,	_	_	_	_
31-3	5461-5465	this	event	giv	_	_
31-4	5466-5469	may	_	_	_	_
31-5	5470-5474	have	_	_	_	_
31-6	5475-5481	caused	_	_	_	_
31-7	5482-5483	a	event[284]	giv[284]	_	_
31-8	5484-5492	slightly	event[284]	giv[284]	_	_
31-9	5493-5497	more	event[284]	giv[284]	_	_
31-10	5498-5508	pronounced	event[284]	giv[284]	_	_
31-11	5509-5517	increase	event[284]	giv[284]	_	_
31-12	5518-5520	of	event[284]	giv[284]	_	_
31-13	5521-5533	postprandial	event[284]|substance[285]	giv[284]|giv[285]	coref	31-18[0_285]
31-14	5534-5541	ethanol	event[284]|substance[285]	giv[284]|giv[285]	_	_
31-15	5542-5546	with	event[284]	giv[284]	_	_
31-16	5547-5553	higher	event[284]|abstract[287]	giv[284]|giv[287]	_	_
31-17	5554-5558	peak	event[284]|abstract[287]	giv[284]|giv[287]	_	_
31-18	5559-5566	ethanol	event[284]|substance|abstract[287]	giv[284]|giv|giv[287]	coref	32-1[290_0]
31-19	5567-5581	concentrations	event[284]|abstract[287]	giv[284]|giv[287]	_	_
31-20	5582-5584	in	event[284]|abstract[287]	giv[284]|giv[287]	_	_
31-21	5585-5589	T1DM	event[284]|abstract[287]|abstract|person[289]	giv[284]|giv[287]|giv|giv[289]	coref	32-10[291_289]
31-22	5590-5598	patients	event[284]|abstract[287]|person[289]	giv[284]|giv[287]|giv[289]	_	_
31-23	5599-5600	.	_	_	_	_

#Text=Elevated endogenous ethanol was also already previously detected in diabetic patients .
32-1	5601-5609	Elevated	substance[290]	giv[290]	_	_
32-2	5610-5620	endogenous	substance[290]	giv[290]	_	_
32-3	5621-5628	ethanol	substance[290]	giv[290]	_	_
32-4	5629-5632	was	_	_	_	_
32-5	5633-5637	also	_	_	_	_
32-6	5638-5645	already	_	_	_	_
32-7	5646-5656	previously	_	_	_	_
32-8	5657-5665	detected	_	_	_	_
32-9	5666-5668	in	_	_	_	_
32-10	5669-5677	diabetic	person[291]	giv[291]	_	_
32-11	5678-5686	patients	person[291]	giv[291]	_	_
32-12	5687-5688	.	_	_	_	_
